Business Context and Reporting Period
Arrivent Biopharma, Inc. (AVBP), a Delaware corporation and emerging growth company, filed this Form 8-K on March 11, 2025. The report details a change in the company's independent registered public accounting firm.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the transition of the external auditor.
Material Changes
- Dismissal of KPMG LLP: The Audit Committee dismissed KPMG LLP as the independent registered public accounting firm on March 11, 2025.
- Reason for Dismissal: The dismissal was not related to any disagreements on accounting principles, financial statement disclosure, or auditing scope. KPMG's reports for fiscal years 2023 and 2024 were unqualified.
- Appointment of PwC: PricewaterhouseCoopers LLP (PwC) was appointed as the new independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Historical Context: The filing references previously reported material weaknesses in internal controls (regarding manual journal entries and nonroutine transactions) that were remediated as of December 31, 2024.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future operations. The primary risk disclosed relates to the historical material weaknesses in internal controls, which the company states have been remediated. No new contingencies or unusual items were reported in this document.
Investor Verification Checklist
- Verify the status of the remediation of internal control material weaknesses as of December 31, 2024, in the most recent Form 10-K.
- Review the letter from KPMG LLP (Exhibit 16.1) to confirm their agreement with the company's statements regarding the dismissal.
- Confirm that no consultations occurred with PwC regarding accounting matters prior to their appointment.